Dr. Klaus Giese
Chief Scientific Officer
Pre-Clinical and Clinical Development of Atu027, a Liposomal siRNA, for Therapy in Oncology
Atu027, a novel RNAi therapeutic composed of liposomally formulated siRNA, is currently being tested in a Phase I clinical trial in oncology. This investigational drug targets the expression of PKN3 in the vascular endothelium and shows inhibition of tumor growth and strong anti-metastatic activity in various pre-clinical models. Latest developments on Atu027 will be discussed.
[ close ]
Information and opinions contained in this broadcast have been compiled or arrived at by the organisation making this presentation. Any statements, information and opinions contained in this broadcast,
in particular those concerning investments and the possible or assumed future performance, costs, dividends, returns, production levels or rates, prices, reserves, divestments, growth or other trend
projections and any estimated earnings are or may be forward looking statements and as such involve risks and uncertainties. Actual results and developments may differ materially from those expressed
or implied by these statements depending on a variety of factors.
This broadcast is brought to you by 3B NEXUS who make no representation or warranty regarding the accuracy or reliability or completeness of any information provided and accepts no liability for any
loss arising from the use hereof. Any reliance you place on such information will be at your sole risk.